addnok 8 mg podjezične tablete
activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 8 mg / 1 tableta - buprenorfin
addnok 8 mg podjezične tablete
activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 8 mg / 1 tableta - buprenorfin
addnok 8 mg podjezične tablete
activase pharmaceuticals ltd. - buprenorfin - podjezična tableta - buprenorfin 8 mg / 1 tableta - buprenorfin
tetmodis 25 mg tablete
aop orphan pharmaceuticals ag - tetrabenazin - tableta - tetrabenazin 25 mg / 1 tableta - tetrabenazin
apo-go 10 mg/ml raztopina za injiciranje ali infundiranje v ampuli
britannia pharmaceuticals limited - apomorfin - raztopina za injiciranje/infundiranje - apomorfin 8,55 mg / 1 ml - apomorfin
apo-go 10 mg/ml raztopina za injiciranje ali infundiranje v ampuli
britannia pharmaceuticals limited - apomorfin - raztopina za injiciranje/infundiranje - apomorfin 8,55 mg / 1 ml - apomorfin
thromboreductin 0,5 mg trde kapsule
aop orphan pharmaceuticals ag - anagrelid - kapsula, trda - anagrelid 0,5 mg / 1 kapsula - anagrelid
xomolix 2,5 mg/ml raztopina za injiciranje
chiesi pharmaceuticals gmbh - droperidol - raztopina za injiciranje - droperidol 2,5 mg / 1 ml - droperidol
aloxi
helsinn birex pharmaceuticals ltd. - palonosetronijev hidroklorid - vomiting; cancer - antiemetics in antinauseants, serotonina (5ht3) antagonisti - aloxi je navedeno v odraslih za:preprečevanje akutne slabosti in bruhanja, povezanih z močno emetogenic rak, kemoterapija,preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenic kemoterapijo raka. aloxi je navedeno v pediatričnih bolnikih od 1 meseca starosti in starejših za:preprečevanje akutne slabosti in bruhanja, povezanih z močno emetogenic rak, kemoterapija in preprečevanje slabosti in bruhanja, povezanih z zmerno emetogenic kemoterapijo raka.
firmagon
ferring pharmaceuticals a/s - degareliks - prostatične neoplazme - endokrini terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.